FCSC - Krystal Biotech: Game-Changing Gene Therapies For Serious Skin Diseases
The Company
Krystal Biotech Inc. (KRYS) is a clinical-stage gene therapy company based in Pittsburgh, PA, which is founded in 2015 and has its IPO in September 2017.
It develops novel, "off-the-shelf", topical gene therapies for serious genetic skin diseases.
Based on the strength of their proprietary technology (to be discussed further below), the company currently focuses on the most severe congenital genetic skin diseases, including their lead indication, Dystrophic Epidermolysis Bullosa (or DEB), as shown within the blue box of the pipeline summary below.
(Source: Company website. blue highlight by